|
|
 |
|
Viewing report
|
|
|
|
Systemic Fungal Infection Therapeutics Market – China
Frost & Sullivan, Nov 2009, Pages: 43
This research service aims to provide an update on the epidemiology of systemic fungal infection, current diagnostic and treatment practices, as well as market landscape in terms of major participants and future trends. It covers the systemic fungal infection therapeutics market in China.
This Frost & Sullivan research service titled Systemic Fungal Infection Therapeutics Market – China provides a comprehensive analysis of the market, the competitive structure, and future trends. The study focuses on drug classes that are dominant in the systemic fungal infections therapeutics market.
Market Overview
Advances in Diagnostic Tests Facilitate More Targeted Approaches to Treatment of Systemic Fungal Infections
With fast-paced advancements in technology, the number of patients diagnosed with systemic fungal infections (SFI) is expected to increase steadily over the next five years. Alongside this development, a high premium on products that are capable of tackling emergent, problematic pathogens will transform market dynamics in treating SFI. Estimates reveal that the global prevalence of SFI has risen to four for every one thousand of the global population. This high incidence of SFI over the years is attributed to the widespread use of broad-spectrum antibiotics, which reduce non-pathogenic bacterial populations that compete with fungi and the growing number of persons with compromised immune systems caused by acquired immune deficiency syndrome (AIDS), immunosuppressant drugs, and chemotherapy agents. Early diagnosis of SFI has been shown to be critical to treatment outcome. 'In China, most physicians prescribe Diflucan oral (Fluconazole) because of its efficacy against Candida albicans and convenience in administering the treatment,' notes the analyst of this research service. 'However, because of high toxicity levels and patient drop outs due to the low tolerance for long duration treatments, physicians have turned more to other medicines such as amphotericin B, voriconazole, and itraconazole.'
In terms of the diagnostic technology available, physicians expect more fungal culture and serology tests to be utilized in the country. SFI drugs in China may remain expensive in the near future, especially with the low presence of generic counterparts. The continuous introduction of new SFI treatment in the country is unlikely to reduce the cost of existing SFI treatments. Although key therapeutics have been in the market to treat the most causative pathogen (Candida Albicans), there is an unmet need to treat more resistant ones such as Aspergillus. 'As more resistant pathogens in SFI emerge, the focus of treatment is directed toward finding the most appropriate mode of treatment in line with universal criteria, such as risk factors, clinical, radiological, microbiological or other diagnostic evidence,' says the analyst. 'The task is made easier for physicians with the growing availability of non-microbiologic and clinical diagnostic techniques, such as Platelia, Fungitell and PNA FISH, to identify the onset of infection.' Greater emphasis is placed on matching antifungal choice to pathogen susceptibility, heightening the demand for rapid typing of pathogens to ensure informed, targeted drug choices. As a result, there is a reduction in the use of prophylaxis in the ‘at-risk’ patient group and empiric therapy in, for example, patients in this group with a persistent fever or other suggestive symptoms.
Considering the relatively niche nature of SFI, it is vital for key companies to differentiate their products, especially as advances in diagnostic techniques bring about a restriction of prescriptions to specific therapeutic uses. As therapeutics shift away from broad and empiric indications, pharmaceutical manufacturers need to position their products to address more specific indications defined by pathogen species (and sub species) and patient populations, rather than a broad spectrum. This gives room for a higher degree of differentiation, protecting the specific drug from generic erosion in the future. The changing epidemiology of causative pathogens has caused the effectiveness of existing therapeutic options to decline. Pharmaceutical manufacturers then need to develop drugs that address specific indications, in terms of pathogen coverage and patient groups, that is, solid organ transplant, cancer, neonates, HIV/AIDS, and surgical patients.
Product samples
A sample for this product is available. Please Login/Register to download this sample.
Customers who bought this item also bought
Systemic Fungal Infection Therapeutics Market – Singapore
Systemic Fungal Infection Therapeutics Market- Taiwan
Systemic Fungal Infection Therapeutics Market Research – Philippines
Systemic Fungal Infection Therapeutics Research – Malaysia
Systemic Fungal Infection Therapeutics Market - Australia
Systemic Fungal Infection Therapeutics Market - South Korea
Systemic Fungal Infection Therapeutics Market – Thailand
Systemic Fungal Infection Therapeutics Market - Hong Kong
Systemic Fungal Infection Therapeutics Market – India
Innovations in Combating Infectious Diseases: Opportunities in Therapeutics and Diagnostics through Application of Proteomics, Genomics, Nanotechnology, and Novel Sources of Lead Generation
|
|
|
|
